Reprogramming T Cells to
Go the Distance
Against Cancer

Our Story
Rick Klausner, M.D.,Founder & Board Chair

Founder's Vision

Lyell Founder and Board Chair Rick Klausner, M.D., shares his vision for conquering oncology’s unfinished business – curative cell therapy for solid tumors.

Our Science icon

Our Science

Technologies designed to address major barriers to successful adoptive cell therapy (ACT) in solid tumors.

Our Pipeline icon

Our Pipeline

Our multi-modal product pipeline targets solid tumor cancers with significant unmet medical need.

Dedicated to Patients

An unwavering focus on science guides our mission to deliver transformative T-cell therapies that can go the distance for patients with solid tumors.

Learn More
Latest News

Lyell Immunopharma Announces the Appointment of Rahsaan Thompson as Chief Legal Officer

SOUTH SAN FRANCISCO, Calif., Sept. 28, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company dedicated to developing curative cell therapies for patients with solid tumors, announced that Rahsaan W.

View All News

Join Our Team

At Lyell, we are driven by our mission and focused on developing transformative therapies to improve the lives of patients.

Join our team of ambitious Lyellites who are committed to curing solid tumor cancers through innovation.

See Open Positions